Compare Stocks: DBVT, PGEN, NAMS, and GMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$10.55 -5.9%	$13.31	$10.47 ▼ $26.18	$663.38M	-1.04	306,606 shs	673,301 shs
GMTX Gemini Therapeutics	$63.61 -2.8%	$75.41	$1.16 ▼ $14.10	$2.76B	-0.12	189,291 shs	771,838 shs
NAMS NewAmsterdam Pharma	$23.20 -4.0%	$25.69	$21.02 ▼ $42.21	$2.77B	0.1	1.14 million shs	1.55 million shs
PGEN Precigen	$8.54 +4.0%	$7.00	$2.99 ▼ $8.98	$3.04B	0.92	4.70 million shs	6.36 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	-4.68%	-3.36%	-16.47%	-29.14%	+11.32%
GMTX Gemini Therapeutics	-0.62%	-0.95%	-16.77%	-14.16%	-0.94%
NAMS NewAmsterdam Pharma	-0.66%	+6.24%	-3.05%	-30.63%	-17.71%
PGEN Precigen	-4.09%	+6.62%	+19.68%	+45.57%	+145.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$10.55 -5.9%	$13.31	$10.47 ▼ $26.18	$663.38M	-1.04	306,606 shs	673,301 shs
GMTX Gemini Therapeutics	$63.61 -2.8%	$75.41	$1.16 ▼ $14.10	$2.76B	-0.12	189,291 shs	771,838 shs
NAMS NewAmsterdam Pharma	$23.20 -4.0%	$25.69	$21.02 ▼ $42.21	$2.77B	0.1	1.14 million shs	1.55 million shs
PGEN Precigen	$8.54 +4.0%	$7.00	$2.99 ▼ $8.98	$3.04B	0.92	4.70 million shs	6.36 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	-4.68%	-3.36%	-16.47%	-29.14%	+11.32%
GMTX Gemini Therapeutics	-0.62%	-0.95%	-16.77%	-14.16%	-0.94%
NAMS NewAmsterdam Pharma	-0.66%	+6.24%	-3.05%	-30.63%	-17.71%
PGEN Precigen	-4.09%	+6.62%	+19.68%	+45.57%	+145.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.67	Moderate Buy	$48.50	359.72% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.73	114.34% Upside
PGEN Precigen	2.83	Moderate Buy	$13.67	60.03% Upside

Current Analyst Ratings Breakdown

Latest DBVT, PGEN, NAMS, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/24/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2026	NAMS NewAmsterdam Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$52.00
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00
8/5/2026	PGEN Precigen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
7/20/2026	NAMS NewAmsterdam Pharma	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$58.00
7/20/2026	NAMS NewAmsterdam Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$5.64M	117.62	N/A	N/A	$4.20 per share	2.51
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
NAMS NewAmsterdam Pharma	$22.50M	123.26	N/A	N/A	$5.97 per share	3.89
PGEN Precigen	$9.68M	314.52	N/A	N/A	$0.06 per share	142.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	11.70	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)

Latest DBVT, PGEN, NAMS, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q3 2026	DBVT DBV Technologies	-$0.1617	N/A	N/A	N/A	$0.66 million	N/A
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	3.72	3.72
GMTX Gemini Therapeutics	N/A	71.49	71.49
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
PGEN Precigen	2.15	4.58	3.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
GMTX Gemini Therapeutics	75.42%
NAMS NewAmsterdam Pharma	89.89%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.06%
GMTX Gemini Therapeutics	12.90%
NAMS NewAmsterdam Pharma	12.74%
PGEN Precigen	41.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
PGEN Precigen	47	356.51 million	208.92 million	Optionable

DBVT, PGEN, NAMS, and GMTX Headlines

Recent News About These Companies

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

October 2 at 9:01 AM | zacks.com

Precigen (NASDAQ:PGEN) Reaches New 52-Week High - Should You Buy?

October 2 at 7:21 AM | americanbankingnews.com

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

October 1 at 5:36 AM | zacks.com

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

September 30 at 1:11 PM | zacks.com

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

September 30 at 1:04 PM | finance.yahoo.com

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

September 30 at 1:00 PM | seekingalpha.com

Precigen (NASDAQ:PGEN) Hits New 12-Month High - Here's What Happened

September 30 at 12:19 PM | marketbeat.com

Head to Head Contrast: Emergent Biosolutions (NYSE:EBS) vs. Precigen (NASDAQ:PGEN)

September 30 at 4:58 AM | americanbankingnews.com

Critical Review: TScan Therapeutics (NASDAQ:TCRX) vs. Precigen (NASDAQ:PGEN)

September 29 at 5:29 AM | americanbankingnews.com

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

September 29 at 1:59 AM | finance.yahoo.com

Precigen (NASDAQ:PGEN) Shares Gap Up After Analyst Upgrade

September 27, 2026 | americanbankingnews.com

Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN

September 27, 2026 | marketbeat.com

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

September 26, 2026 | finance.yahoo.com

B Riley Securities initiates coverage of Precigen at buy

September 26, 2026 | msn.com

B. Riley Financial Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"

September 26, 2026 | marketbeat.com

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

September 26, 2026 | finance.yahoo.com

Precigen (NASDAQ:PGEN) Shares Gap Up - Here's What Happened

September 25, 2026 | marketbeat.com

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

September 24, 2026 | zacks.com

Corient Private Wealth LP Sells 577,406 Shares of Precigen, Inc. $PGEN

September 24, 2026 | marketbeat.com

Precigen (NASDAQ:PGEN) Hits New 12-Month High - What's Next?

September 23, 2026 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Hits New 1-Year High - Time to Buy?

September 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, PGEN, NAMS, and GMTX Company Descriptions

DBV Technologies NASDAQ:DBVT

$10.55 -0.66 (-5.89%)

Closing price 04:00 PM Eastern

Extended Trading

$10.54 -0.01 (-0.05%)

As of 04:43 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Gemini Therapeutics NASDAQ:GMTX

$63.61 -1.85 (-2.83%)

As of 10/1/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$23.20 -0.96 (-3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$23.72 +0.53 (+2.26%)

As of 07:14 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen NASDAQ:PGEN

$8.54 +0.33 (+4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$8.50 -0.04 (-0.47%)

As of 07:03 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, PGEN, NAMS, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, PGEN, NAMS, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, PGEN, NAMS, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, PGEN, NAMS, and GMTX Company Descriptions

DBV Technologies NASDAQ:DBVT

Gemini Therapeutics NASDAQ:GMTX

NewAmsterdam Pharma NASDAQ:NAMS

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, PGEN, NAMS, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, PGEN, NAMS, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, PGEN, NAMS, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, PGEN, NAMS, and GMTX Company Descriptions

DBV Technologies NASDAQ:DBVT

Gemini Therapeutics NASDAQ:GMTX

NewAmsterdam Pharma NASDAQ:NAMS

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools